The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

The United States Government As Represented by the Department of Veterans Affairs

Protein Design Labs, Inc.

Thomas Alexander Waldmann

Ira H Pastan

Cary L Queen

Roland Martin

Bibiana Bielekova

Henry McFarland

Liyanage Parakrama Perera

David J FitzGerald

Vijay K Chaudhary

Pin-Yu Perera

Kevin Charles Conlon

Jay A Berzofsky

Warren Jaye Leonard

David J Fitzgerald

Vijay Kumar Chaudhary

Sang-Kon Oh

Pin Yu Perera

A chimeric antigen receptor is disclosed that includes: (a) an scFv comprising a light chain variable domain (V) and a heavy chain variable domain (V), wherein the scFv specifically binds to CCR4; (b) a hinge and transmembrane domain from CD8; (c) an intracellular 4-1BB signaling domain; and (d) an intracellular CD3 zeta signaling domain, wherein (a)-(d) are in N to C terminal order. Uses of the chimeric antigen receptor, such as for treating a malignancy, are also disclosed.

Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use

The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.

Recombinant vaccine viruses expressing IL-15 and methods using the same

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist

Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist

The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection.Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.

Method for treating malignancy and autoimmune disorders in humans using tac antibodies

The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.

Constructs encoding recombinant antibody-toxin fusion proteins

The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.

Recombinant antibody-toxin fusion protein

The present invention is related to the field of receptor molecules and complexes. More particularly, the present invention is related to a new polypeptide receptor for interleukin-2 having a molecular weight of about 70-75,000, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide, and recombinant interleukins capable of binding to the new receptor. Various applications of the p70-75 receptor, the anti-p70-75 antibodies and IL-2W.sub.1 and IL2W.sub.2 have also been described.

Interleukin 2 receptor and applications thereof

Growing community of inventors

Silver Springs, MD, United States of America

Thomas Alexander Waldmann